Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Moda
Completed
National Cancer Institute (NCI)
Phase 2
1997-02-01
Positron Emission Tomography (PET scanning) is performed using a total dose of less than 50
mRad per patient visit. Fludeoxyglucose F 18 (FDG) is injected intravenously over 2 min.
Initial dynamic images will be obtained over the heart. Emission imaging will work from the
midcervical region down to the perineal region.
For CEA scanning, radiolabeled antibody, arcitumomab (IMMU-4), is injected intravenously over
5 min. A single photon emission computed tomography (SPECT) transmission scan is performed
over the same regions as the emission scans. Total dose from transmission scans should be no
more than 20 mRad per patient visit.
Patients then undergo exploratory laparotomy performed by two surgeons, one blinded to the
results of the CEA-Scan and PET scan.
At the completion of all exploration, all identified disease is biopsied for pathologic
analysis and any resectable disease is removed.
Patients are followed every 3 months for 1 year, every 6 months for the second year, and then
after 3 years.
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
Completed
National Cancer Institute (NCI)
Phase 2
1999-02-01
RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to
determine the extent of disease.
PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect
metastatic disease in patients who have stage III or stage IV melanoma.
PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma
Completed
Memorial Sloan Kettering Cancer Center
Phase 2
1999-02-01
RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to
determine the extent of disease.
PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect
metastatic disease in patients who have stage III or stage IV melanoma.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
